News

Yahoo Finance1y
Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders
Sorrento Therapeutics, Inc. SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life ...
WGN Radio1y
Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded a $4.6 million contract from the National Institute of Allergy and ...
The Globe and Mail2y
Why Sorrento Therapeutics' Shares Tumbled 23.4% in September
Sorrento, popular with retail investors, has been struggling financially. Through six months, the biotech company reported that while revenue was up 7% year over year to $29.7 million, the company ...
WKRN-TV1y
Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase ...
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ) today announced positive results from a China phase IIa study of Abivertinib on R/R MZL and its plan for a ...
The Globe and Mail2y
Why Sorrento Therapeutics Stock Crashed Today
What goes up usually comes down, and that's exactly what happened with Sorrento Therapeutics(NASDAQ: SRNE) today. Shares of Sorrento were crashing 30.4% as of 3:38 p.m. ET on Wednesday after ...
NBC4 Columbus1y
Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment ...
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ) announced today the full enrollment in a pivotal Phase 3 study of Sorrento’s oral M pro inhibitor ...
KTLA2y
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce the Closing of their ...
2022 under the ticker symbols “SCLX” and “SCLXW,” respectively Sorrento owns over 96% of Scilex PALO ALTO and NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq ...
WAVY-TV2y
Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19
SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the FDA clearance of a Phase 1 study of its oral main viral protease (M pro ...
WFLA News Channel 81y
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the ...
All study objectives were met, demonstrating safety across dose groups and confirming efficacy and durability at the selected doses against placebo (lidocaine) and active control (steroid).All RTX ...